We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Imfinzi

News List

AstraZeneca's Imfinzi survival win shores up the one lung cancer advantage it has fiercepharma
May 29, 2018
AstraZeneca’s Imfinzi already has an FDA approval in the lung cancer maintenance setting under its belt, something none of its rivals will be able to say for a while. And Friday, it hit another key benchmark to stretch out that lead.
Cancer drug study placed on hold after patient death pharmatimes
March 14, 2018
US regulators have placed on hold a clinical trial testing a combination of Advaxis’ axalimogene filolisbac and AstraZeneca's Imfinzi after a patient died from respiratory failure.
Imfinzi Granted Breakthrough Therapy Designation by US FDA americanpharmaceuticalreview
August 02, 2017
AstraZeneca and MedImmune announced the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Imfinzi (durvalumab) for the treatment of patients...
Imfinzi wins breakthrough therapy designation europeanpharmaceuticalreview
August 01, 2017
AstraZeneca and MedImmune, have today announced that the US Food and Drug Administration has granted breakthrough therapy designation for Imfinzi for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer…

Previous page 1 2 3 4 5 Next page